You just read:

Daiichi Sankyo Announces ENLIVEN Phase 3 Study of Pexidartinib Met Primary Endpoint in Tenosynovial Giant Cell Tumor

News provided by

Daiichi Sankyo Company, Limited

Oct 31, 2017, 00:00 ET